Company Overview of MedImmune, LLC
MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...
One MedImmune Way
Gaithersburg, MD 20878
Founded in 1987
Key Executives for MedImmune, LLC
Vice President of Finance
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Compensation as of Fiscal Year 2015.
MedImmune, LLC Key Developments
Advaxis, Inc and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac in Combination With Durvalumab
Aug 20 15
Advaxis, Inc. announced that enrollment has commenced in a phase I/II clinical trial of axalimogene filolisbac (ADXS-HPV), Advaxis's investigational Lm Technology™ immunotherapy, in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), for the treatment of patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The two-part, open-label Phase I/II study is designed to evaluate the safety and efficacy of axalimogene filolisbac as a monotherapy and in combination with durvalumab in approximately 66 patients. Phase I is a dose-confirmation combination study with axalimogene filolisbac and durvalumab, which is expected to establish the maximum tolerated dose. The Phase II portion of the study will randomize patients to receive axalimogene filolisbac monotherapy, durvalumab monotherapy, or the combination.
MedImmune Teams Up With Mirati Therapeutics on Lung Cancer Trials
Aug 12 15
MedImmune and Mirati Therapeutics are collaborating on early-phase clinical trials to evaluate the safety and efficacy of investigational drugs in patients with non-small cell lung cancer. The trials, expected to begin next year, will combine MedImmune's durvalumab, an anti-PDL1 immune checkpoint inhibitor, with Mirati's mocetinostat, a spectrum-selective histone deacetylase inhibitor. Under the agreement, Mirati will conduct and fund the initial trials and MedImmune will supply durvalumab. If those studies show positive results, Medimmune will have an exclusive period to negotiate a commercial license for the combination. On their own, mocetinostat has FDA orphan drug designation as a treatment for diffuse large B-cell lymphoma and durvalumab has been accelerated into Phase 3 clinical development in NSCLC and head and neck cancers.
Medimmune Appoints Christopher Rhodes as Head of Cardiovascular, Metabolic Disease Research
Jul 14 15
MedImmune announced that Christopher Rhodes, Ph.D., has joined the company as Vice President, Cardiovascular and Metabolic Disease (CVMD) Research. Dr. Rhodes will be responsible for developing and growing MedImmune's research base in CVMD in both the US and UK, and contributing to the product development goals and vision across the CVMD therapeutic area. Dr. Rhodes joins MedImmune from the University of Chicago, where he was Research Director at the Kovler Diabetes Center, the Kovler Family Professor of Endocrinology, and Chair of the Committee on Molecular Metabolism & Nutrition and Biomedical Sciences Cluster of the Biological Sciences Division.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 4, 2014